Actuate Therapeutics (ACTU) Competitors

$8.25

+0.24 (+3.00%)

(As of 03:26 PM ET)

Stock Analysis Chart Competitors Financials Headlines Insider Trades SEC Filings Trends

ACTU vs. ITOS, MREO, YMAB, ALEC, TERN, ELYM, SIGA, APLT, SLN, and ARCT

Should you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include iTeos Therapeutics (ITOS), Mereo BioPharma Group (MREO), Y-mAbs Therapeutics (YMAB), Alector (ALEC), Terns Pharmaceuticals (TERN), Eliem Therapeutics (ELYM), SIGA Technologies (SIGA), Applied Therapeutics (APLT), Silence Therapeutics (SLN), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry.

Actuate Therapeutics vs.

iTeos Therapeutics (NASDAQ:ITOS) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

: 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 78.3% of Actuate Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 19.9% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Actuate Therapeutics' return on equity of 0.00% beat iTeos Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
iTeos Therapeutics N/A -18.18% -15.86%
Actuate Therapeutics N/A N/A N/A
: iTeos Therapeutics presently has a consensus price target of $30.50, indicating a potential upside of 122.47%. Given iTeos Therapeutics' higher possible upside, equities research analysts plainly believe iTeos Therapeutics is more favorable than Actuate Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iTeos Therapeutics
0 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
3.00
Actuate Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Actuate Therapeutics has lower revenue, but higher earnings than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iTeos Therapeutics $35M 13.21 -$112.64M -$3.78 -3.39
Actuate Therapeutics N/A N/A N/A $0.15 53.40
: iTeos Therapeutics received 35 more outperform votes than Actuate Therapeutics when rated by MarketBeat users.
Company Underperform Outperform
iTeos Therapeutics Outperform Votes
35
76.09%
Underperform Votes
11
23.91%
Actuate Therapeutics N/A N/A
: In the previous week, iTeos Therapeutics had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 9 mentions for iTeos Therapeutics and 6 mentions for Actuate Therapeutics. iTeos Therapeutics' average media sentiment score of 0.42 beat Actuate Therapeutics' score of 0.31 indicating that iTeos Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iTeos Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Actuate Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-18.18%	-15.86%
Actuate Therapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Actuate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$35M	13.21	-$112.64M	-$3.78	-3.39
Actuate Therapeutics	N/A	N/A	N/A	$0.15	53.40

Company	Underperform	Outperform
iTeos Therapeutics	Outperform Votes 35 76.09%	Underperform Votes 11 23.91%
Actuate Therapeutics	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iTeos Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actuate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iTeos Therapeutics beats Actuate Therapeutics on 7 of the 12 factors compared between the two stocks.

Ad Brownstone Research

Introducing the Perceptron

On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.

Just click here to register.

Get Actuate Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export to Excel

Metric	Actuate Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$153.07M	$7.30B	$5.32B	$8.16B
Dividend Yield	N/A	4.38%	4.31%	4.10%
P/E Ratio	53.40	17.41	130.98	18.33
Price / Sales	N/A	272.21	1,791.51	73.46
Price / Cash	N/A	36.36	35.70	31.78
Price / Book	N/A	6.16	4.92	4.78
Net Income	N/A	$146.22M	$110.10M	$222.19M
7 Day Performance	-3.14%	8.94%	117.59%	6.80%
1 Month Performance	-7.93%	14.55%	125.24%	10.65%
1 Year Performance	N/A	20.26%	155.55%	14.66%

Actuate Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITOS iTeos Therapeutics	1.9407 of 5 stars 1.94 / 5 stars	$16.70 -1.2%	$30.50 +82.6%	+35.6%	$603.25M	$35M	-4.42	90	Analyst Forecast Gap Down High Trading Volume
MREO Mereo BioPharma Group	2.5927 of 5 stars 2.59 / 5 stars	$4.28 -2.5%	$7.50 +75.2%	+174.4%	$600.30M	$1M	0.00	40	Analyst Forecast
YMAB Y-mAbs Therapeutics	3.5253 of 5 stars 3.53 / 5 stars	$13.74 +3.8%	$21.14 +53.9%	+175.4%	$590.10M	$84.82M	-28.04	150
ALEC Alector	4.5037 of 5 stars 4.50 / 5 stars	$6.03 +7.5%	$14.67 +143.2%	-8.1%	$581.20M	$55.28M	-4.37	270	Short Interest ↓
TERN Terns Pharmaceuticals	3.9588 of 5 stars 3.96 / 5 stars	$8.96 -5.8%	$14.50 +61.9%	+74.9%	$579.21M	$1M	-7.11	40	Analyst Forecast Short Interest ↑ High Trading Volume
ELYM Eliem Therapeutics	0.2561 of 5 stars 0.26 / 5 stars	$8.46 +5.8%	N/A	+212.2%	$567.33M	N/A	-15.96	20	Short Interest ↑
SIGA SIGA Technologies	2.8825 of 5 stars 2.88 / 5 stars	$7.90 +0.4%	N/A	+72.9%	$563.82M	$139.92M	7.18	40	Positive News
APLT Applied Therapeutics	3.9919 of 5 stars 3.99 / 5 stars	$4.89 +0.2%	$11.25 +130.1%	+162.9%	$561.62M	$9.99M	-2.66	30
SLN Silence Therapeutics	3.2198 of 5 stars 3.22 / 5 stars	$18.69 +0.6%	$57.20 +206.0%	+87.8%	$559.39M	$31.55M	-16.11	100	Short Interest ↓ Positive News
ARCT Arcturus Therapeutics	2.2943 of 5 stars 2.29 / 5 stars	$20.75 +4.2%	$71.40 +244.1%	-27.3%	$558.80M	$169.93M	-5.31	180	News Coverage